What Clever Leaves does

Clever Leaves International Inc. (NASDAQ: CLVR) is a Colombia-based, vertically integrated medical cannabis operator founded in 2016 and headquartered in New York. The company cultivates pharmaceutical-grade cannabis at a 1.8 million sq. ft. outdoor footprint in Pesca, Boyacá, and processes it through an EU GMP-certified extraction facility in Tocancipá, Cundinamarca, with installed capacity of 104,400 kg of dried flower per year (expandable to 324,000 kg). Its portfolio spans raw materials — CBD isolate, full spectrum, broad spectrum, distillate and bulk extracts, plus dried flower — and finished high-CBD oral solutions (e.g., OS 20%CBD and OS 10%CBD) supplied under white-label agreements. EU GMP certification, GACP-compliant flower, and approvals in 15+ countries are the regulatory backbone of the business.

The company's commercial model is B2B: it supplies licensed pharmaceutical companies and distributors rather than retail patients. Customer concentration is anchored by multi-year agreements with Cansativa (Germany, where Clever Leaves has also taken an equity stake), Cannatrek and IDT Australia (Australia), GreenCare (Brazil, with a $4M minimum three-year purchase commitment), and CBD Life (Mexico). Go-to-market combines direct enterprise sales from Colombian and U.S. headquarters with in-country channel partners handling local distribution, regulatory, and logistics requirements. Pricing is quote-based and not publicly disclosed, consistent with negotiated pharma supply contracts.

Clever Leaves monetizes export volume rather than retail brand pricing. Its competitive positioning rests on a Colombian cost base (outdoor cultivation, 100% rainwater irrigation, carbon-neutral production at 16 kg CO2 per kg dried flower vs. 2,300–5,200 kg for indoor cultivation) combined with EU GMP-grade quality, enabling entry into regulated international medical cannabis markets where indoor producers in North America and Europe face higher unit costs. Northern Swan Holdings is identified as a financial sponsor; the company has raised disclosed equity funding of approximately $50M+ since 2018 and has transitioned to a publicly listed entity on NASDAQ under ticker CLVR.

Name

Clever Leaves

Legal name

Clever Leaves International Inc.

Website

https://cleverleaves.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

101–250 employees

Short description

Clever Leaves International Inc. (NASDAQ: CLVR) is a Colombia-based, EU GMP-certified medical cannabis producer supplying pharmaceutical-grade extracts and white-label finished products to licensed pharmaceutical distributors across Germany, Australia, Brazil, Mexico, and other international markets.

Ownership category

akta.pro rank

Product category

Pharmaceutical-Grade Medical Cannabis Manufacturing

NAICS

Medicinal and Botanical Manufacturing (325411)

SIC

Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)

akta.pro primary industry

Medicinal Plant Farming (Botanical/Pharmaceutical Crops) (AFAGAGAE)

Keywords

• Medical cannabis extracts
• Pharmaceutical-grade cannabis
• Outdoor cannabis cultivation
• Cannabis API manufacturing
• CBD isolate production

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. B2B Medical Cannabis Product Sales: Clever Leaves generates revenue through selling medical cannabis extracts, including CBD isolate, full spectrum, broad spectrum, distillate, and bulk extracts, as well as finished products (oral solutions) to pharmaceutical companies and licensed distributors globally. The company operates on a product supply model with multi-year commercial agreements.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels3 records

Core offering

Clever Leaves is a vertically integrated B2B producer of pharmaceutical-grade medical cannabis, operating large-scale outdoor cultivation in Pesca, Boyacá (Colombia) and an EU GMP-certified extraction plant in Tocancipá, Cundinamarca, with 104,400 kg of annual dried-flower extraction capacity expanding to 324,000 kg. The company sells dried flower, CBD isolate, full spectrum, broad spectrum, distillate, and bulk extracts, plus finished oral solutions and white-label high-CBD products, to licensed pharmaceutical companies and distributors in Germany, Australia, Brazil, Mexico, Israel, and Peru under multi-year commercial supply agreements.

Product overview

Clever Leaves is a vertically integrated B2B producer of medical cannabis and hemp extracts operating from Colombia. The company offers a comprehensive product portfolio spanning raw materials (dry flower, CBD isolates, full spectrum, broad spectrum, and distillate extracts) and finished pharmaceutical products (high-CBD oral solutions). All products are produced under EU GMP-certified conditions, with cultivation in Pesca, Boyacá and extraction in Tocancipá, Cundinamarca. The company supplies pharmaceutical companies globally through commercial partnerships in Germany, Australia, Brazil, Mexico, and Israel.

Differentiator

Problem solved

Functional benefit

Products and services

• Dry Flower (Medical Cannabis) Medical-grade cannabis dried flower cultivated outdoors in Colombia under GACP-compliant processes and exported as a bulk botanical raw material to licensed pharmaceutical distributors in Germany, Israel, and Australia.
• CBD Isolate Pure crystalline CBD isolate extracted from cannabis biomass at the EU GMP-certified Tocancipá facility and supplied as a pharmaceutical-grade active ingredient to manufacturers and formulators.
• Full Spectrum Extract Full-spectrum cannabis extract containing the plant's complete cannabinoid and terpene profile, produced under EU GMP for use as a pharmaceutical API and ingredient in finished formulations.
• Broad Spectrum Extract Broad-spectrum cannabis extract containing multiple cannabinoids and terpenes with THC removed or reduced to trace levels, manufactured under EU GMP for pharmaceutical-grade applications.
• Cannabis Distillate Refined cannabis distillate with concentrated cannabinoid content produced under EU GMP for pharmaceutical and product-manufacturing applications.
• Bulk Cannabis Extract Bulk-format cannabis extract supplied for use in downstream formulation and manufacturing of finished cannabis-derived products.
• Oral Solutions (OS 20%CBD and OS 10%CBD) Pharmaceutical-grade oral cannabis solutions with specified CBD content (OS 20%CBD and OS 10%CBD) supplied to distribution partners for white-label commercialization in markets such as Australia.
• High-CBD Finished Cannabis Products (White-Label) White-label, high-CBD finished cannabis-derived products licensed and distributed by pharmaceutical partners (e.g., GreenCare in Brazil) under their own brand, manufactured by Clever Leaves under EU GMP.

Quantifiable outcome

• 16 kg CO2 per kg dried flower production vs 2,300-5,200 kg for traditional indoor cultivation
• +2 more outcomes

Named customers5 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core.

• CansativacoreChannel Partner/ Reseller/ DistributorCansativa is a Frankfurt-based certified importer and distributor of medical cannabis products throughout Germany. Clever Leaves made an investment in Cansativa to accelerate participation in the German medical cannabis market. Clever Leaves supplies medical cannabis extracts and oral solutions produced in their EU-GMP certified facilities in Colombia.
• CannatrekcoreChannel Partner/ Reseller/ DistributorClever Leaves has a two-year supply commercial agreement with Cannatrek, providing white label finished products (OS 20%CBD and OS 10%CBD) since August 2020. The agreement offers products not currently available in Australia and strongly positions both parties in the rapidly growing Australian medical cannabis market.
• Institute of Drug Technology (IDT) AustraliacoreChannel Partner/ Reseller/ DistributorCommercial partnership with pharmaceutical manufacturing company IDT Australia to supply bulk GACP certified flowers from Clever Leaves' Portugal facility. This marked the first commercial shipment of Clever Leaves' dry flower to Australia. Clever Leaves is positioned as a dependable supplier meeting IDT's stringent GMP requirements.
• GreenCarecoreChannel Partner/ Reseller/ DistributorThree-year commercial agreement with GreenCare, a leading pharmaceutical company in the Brazilian cannabinoids market. GreenCare will license and distribute certain Clever Leaves' white label finished cannabis-derived products. The agreement provides that GreenCare will purchase at least $4M of product.
• CBD Life Holding SAPI de CVcoreChannel Partner/ Reseller/ DistributorActive pharmaceutical ingredient (API) supply agreement with CBD Life, an emerging leader in the Mexican cannabis industry. Clever Leaves will act as the API supplier for the development and manufacture of CBD Life's medical cannabis products, commencing with CBD isolate, with aims to be the ongoing supplier of required APIs.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Flora Growth: Colombia-based cannabis cultivator and distributor with international distribution focus. Directly comparable Colombian operating base, cultivation focus, and pursuit of European and Latin American medical cannabis markets.
• OrganiGram Holdings: Canadian licensed producer of medical cannabis with international export operations. Comparable in EU GMP-certified production and B2B supply model to pharmaceutical customers, though focused more on Canadian and European markets.
• CannTrust / CannaRoyalty (now PharmHouse): Canadian licensed producer (now restructured) with EU GMP certification and medical cannabis export operations. Historically comparable EU GMP-certified B2B supply model for European markets.
• Aurora Cannabis: Canadian licensed producer of medical and recreational cannabis with global distribution including Europe and Latin America. Directly comparable as a vertically integrated cultivator and extractor selling pharmaceutical-grade cannabis to international markets, though at much larger scale.
• MediPharm Labs: Canadian cannabis extractor specializing in cannabinoid-based derivatives and bulk extracts for B2B customers. Closely comparable as a focused extractor business with pharmaceutical-grade quality positioning serving similar international buyers.
• Avicanna: Canadian-Colombian biopharmaceutical company focused on medical cannabis with cultivation operations in Colombia and commercial distribution in Latin America. Closely comparable Colombian cultivation base and pharmaceutical-grade positioning, though smaller scale.
• Khiron Life Sciences: Colombia-based medical cannabis producer focused on Latin American and European markets. Directly comparable operating model with Colombian cultivation base and EU GMP-certified production targeting similar European and LatAm distribution channels.

Broad incumbents

• Canopy Growth: Major Canadian cannabis producer with international medical cannabis distribution including Germany and other European markets. Comparable EU GMP-certified production and B2B pharmaceutical supply relationships, though broader in scope including recreational products.
• Verano Holdings: Multi-state US cannabis operator with vertically integrated cultivation, processing, and retail. Less directly comparable as US-focused with no significant Colombian operations, but relevant as a public peer benchmark for cannabis operator valuations.
• Tilray Brands: Large multi-national cannabis operator with cultivation in Canada, Portugal, and Germany. Comparable B2B medical cannabis supply model and EU GMP-certified operations; broader portfolio including consumer brands and beverages makes Clever Leaves a more focused alternative.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/clever_leaves
• LinkedInlinkedin.com/company/clever-leaves

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds6 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Clever Leaves